Tie-Up Moves Kangstem's Novel Stem Cell Therapy Towards Globalization
Executive Summary
Helped by a new partnership with Belgium-based MaSTherCell, the South Korean biotech is aiming to initially challenge the European market with a stem cell therapy for atopic dermatitis, derived from human umbilical cord blood.
You may also be interested in...
Kangstem Soothes Investors, Finds Hope In New Trials For Furestem In Atopic Dermatitis
After the much anticipated Phase III South Korean clinical trial of its cord blood-derived stem cell therapy for atopic dermatitis failed to meet its primary endpoint, Kangstem Biotech shifts tactics to focus on repeated dose and combo trials in the hope of better efficacy data.
Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing
Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals...
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.